Prostasin, proteases, and preeclampsia.
暂无分享,去创建一个
[1] L. Vogel,et al. Prostasin and matriptase (ST14) in placenta from preeclamptic and healthy pregnant women , 2016, Journal of hypertension.
[2] Y. Li,et al. Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction. , 2015, The Journal of clinical endocrinology and metabolism.
[3] R. Zhou,et al. Increased expression of prostasin contributes to early-onset severe preeclampsia through inhibiting trophoblast invasion , 2014, Journal of Perinatology.
[4] J. Alexander,et al. Role of chymase in preeclampsia. , 2013, Current vascular pharmacology.
[5] S. Arora,et al. Prostasin: An Epithelial Sodium Channel Regulator , 2013, Journal of biomarkers.
[6] Yang Xia,et al. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. , 2013, Circulation research.
[7] H. Snieder,et al. Urinary prostasin excretion is associated with adiposity in nonhypertensive African-American adolescents , 2013, Pediatric Research.
[8] F. Frey,et al. Vascular Endothelial Growth Factor-A and Aldosterone: Relevance to Normal Pregnancy and Preeclampsia , 2013, Hypertension.
[9] Q. Wu,et al. Role of corin and atrial natriuretic peptide in preeclampsia. , 2013, Placenta.
[10] Karina K. Hansen,et al. Reduced Prostasin (CAP1/PRSS8) Activity Eliminates HAI-1 and HAI-2 Deficiency–Associated Developmental Defects by Preventing Matriptase Activation , 2012, PLoS genetics.
[11] J. Kingdom,et al. Animal models of preeclampsia; uses and limitations. , 2011, Placenta.
[12] F. Frey,et al. Regulation of placental growth by aldosterone and cortisol. , 2010, Endocrinology.
[13] A. Dominiczak,et al. Preeclampsia and future maternal health , 2010, Journal of hypertension.
[14] K. Tomita,et al. Urinary prostasin in humans: relationships among prostasin, aldosterone and epithelial sodium channel activity , 2009, Hypertension Research.
[15] Asif Ahmed,et al. Autoantibody From Women With Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-Cells Signaling , 2008, Hypertension.
[16] R. Lafayette,et al. Pathophysiology of the clinical manifestations of preeclampsia. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[17] A Metin Gülmezoglu,et al. WHO analysis of causes of maternal death: a systematic review , 2006, The Lancet.
[18] P. Rosso,et al. Time Course of Maternal Plasma Volume and Hormonal Changes in Women With Preeclampsia or Fetal Growth Restriction , 2006, Hypertension.
[19] O. Olivieri,et al. Urinary Prostasin: A Candidate Marker of Epithelial Sodium Channel Activation in Humans , 2005, Hypertension.
[20] T. Libermann,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.